Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050812 | 1.00 | KCNK3 (0.41) | KCNK3PTGER4PTGDR2CYP1A2CYP3A4 | |
| SCHEMBL1048113 | 0.92 | ENPP2 (0.41) | KCNK3PTGER4PTGDR2CYP1A2CYP3A4 | |
| SCHEMBL1048115 | 0.92 | ENPP2 (0.41) | KCNK3PTGER4PTGDR2CYP1A2CYP3A4 | |
| SCHEMBL996501 | 0.90 | AKR1B1 (0.43) | PTGER4PTGDR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4102096 | 0.90 | AKR1B1 (0.43) | PTGER4PTGDR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1049710 | 0.90 | NR1H2 (0.40) | PTGDR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1049709 | 0.90 | NR1H2 (0.40) | PTGDR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1048530 | 0.89 | KCNK3 (0.39) | KCNK3PTGER4PTGDR2CYP1A2CYP3A4 | |
| SCHEMBL1048528 | 0.89 | KCNK3 (0.39) | KCNK3PTGER4PTGDR2CYP1A2CYP3A4 | |
| SCHEMBL1049284 | 0.89 | KCNK3 (0.41) | KCNK3PTGER4PTGDR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-02 | — | — | US | claimed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | claimed |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-02 | — | — | US | disclosed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | TRAP1, HSPE1, HSF1 | KCNK3 3815/4885PTGER4 2999/4885PTGDR2 3663/4885 |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | KCNK3 1808/4885PTGER4 2483/4885PTGDR2 828/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | KCNK3 145/4885PTGER4 2890/4885PTGDR2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.